{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T04:12:19Z","timestamp":1750219939000,"version":"3.37.3"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T00:00:00Z","timestamp":1669680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T00:00:00Z","timestamp":1669680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["U01HL128606","U01HL128626"],"award-info":[{"award-number":["U01HL128606","U01HL128626"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s10557-022-07392-2","type":"journal-article","created":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T07:30:29Z","timestamp":1669707029000},"page":"447-457","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Safety and Efficacy of CYP2C19 Genotype-Guided Escalation of P2Y12 Inhibitor Therapy After Percutaneous Coronary Intervention in Chronic Kidney Disease: a Post Hoc Analysis of the TAILOR-PCI Study"],"prefix":"10.1007","volume":"38","author":[{"given":"Roy O.","family":"Mathew","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6440-8492","authenticated-orcid":false,"given":"Mandeep S.","family":"Sidhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charanjit S.","family":"Rihal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Lennon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"El-Hajjar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil","family":"Yager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radmila","family":"Lyubarova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khaled","family":"Abdul-Nour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Weitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. Fearghas","family":"O\u2019Cochlain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vishakantha","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin","family":"Levisay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Marzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Graham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vlad","family":"Dzavik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek","family":"So","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaun","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yves D.","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naveen","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael E.","family":"Farkouh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,29]]},"reference":[{"key":"7392_CR1","doi-asserted-by":"crossref","unstructured":"\u00c5kerblom A, Wallentin L, Siegbahn A, et al. Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes: results from the platelet inhibition and patient outcomes study. Clin Chem. 2012 Jan; 58(1):190\u20139. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/22126936\/","DOI":"10.1373\/clinchem.2011.171520"},{"issue":"6","key":"7392_CR2","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.amjcard.2019.06.001","volume":"124","author":"L Cilia","year":"2019","unstructured":"Cilia L, Sharbaugh M, Marroquin OC, et al. Impact of chronic kidney disease and anemia on outcomes after percutaneous coronary revascularization. Am J Cardiol. 2019;124(6):851\u20136.","journal-title":"Am J Cardiol."},{"key":"7392_CR3","doi-asserted-by":"crossref","unstructured":"Watanabe Y, Mitomo S, Naganuma T, et al. Impact of chronic kidney disease in patients with diabetes mellitus after percutaneous coronary intervention for left main distal bifurcation (from the Milan and New\u2013Tokyo (MITO) Registry). Am J Cardiol. 2021 [cited 2021 Feb 7];138:33\u20139. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33058802\/","DOI":"10.1016\/j.amjcard.2020.10.021"},{"issue":"1","key":"7392_CR4","doi-asserted-by":"publisher","first-page":"17673","DOI":"10.1038\/s41598-018-35982-4","volume":"8","author":"MJ Lin","year":"2018","unstructured":"Lin MJ, Yang WC, Chen CY, et al. Hypertension and chronic kidney disease affect long-term outcomes in patients with stable coronary artery disease receiving percutaneous coronary intervention. Sci Rep. 2018;8(1):17673.","journal-title":"Sci Rep"},{"key":"7392_CR5","doi-asserted-by":"publisher","first-page":"e008708","DOI":"10.1161\/JAHA.118.008708","volume":"7","author":"M Natsuaki","year":"2018","unstructured":"Natsuaki M, Morimoto T, Yamaji K, et al. Prediction of thrombotic and bleeding events after percutaneous coronary intervention: CREDO-Kyoto thrombotic and bleeding risk scores. J Am Heart Assoc [Internet]. 2018;7:e008708.","journal-title":"J Am Heart Assoc [Internet]"},{"key":"7392_CR6","doi-asserted-by":"crossref","unstructured":"Siddiqi OK, Smoot KJ, Dufour AB, et al. Outcomes with prolonged clopidogrel therapy after coronary stenting in patients with chronic kidney disease. Heart [Internet]. BMJ Publishing Group Ltd and British Cardiovascular Society; 2015 [cited 2020 Aug 18];101:1569\u201376. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26209334","DOI":"10.1136\/heartjnl-2014-307168"},{"key":"7392_CR7","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1160\/th14-04-0302","volume":"112","author":"NJ Breet","year":"2014","unstructured":"Breet NJ, de Jong C, Bos WJ, et al. The impact of renal function on platelet reactivity and clinical outcome in patients undergoing percutaneous coronary intervention with stenting. Thromb Haemost Germany. 2014;112:1174\u201381.","journal-title":"Thromb Haemost Germany"},{"key":"7392_CR8","doi-asserted-by":"crossref","unstructured":"Wu Y, Song Y, Pan Y, Gong Y, Zhou Y. High on-clopidogrel platelet reactivity and chronic kidney disease: a meta-analysis of literature studies. Scand Cardiovasc J. 2019 [cited 2022 Sep 30]. p. 55\u201361. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/30909763\/","DOI":"10.1080\/14017431.2019.1598571"},{"key":"7392_CR9","doi-asserted-by":"crossref","unstructured":"Triska J, Maitra N, Deshotels MR, et al. A comprehensive review of the pleiotropic effects of ticagrelor. Cardiovasc Drugs Ther. 2022.","DOI":"10.1007\/s10557-022-07373-5"},{"key":"7392_CR10","doi-asserted-by":"publisher","first-page":"e007811","DOI":"10.1161\/CIRCINTERVENTIONS.119.007811","volume":"12","author":"NL Pereira","year":"2019","unstructured":"Pereira NL, Rihal CS, So DYF, et al. Clopidogrel pharmacogenetics. State-of-the-Art Review and the TAILOR-PCI Study. Circ Cardiovasc Interv. 2019;12:e007811.","journal-title":"Circ Cardiovasc Interv."},{"issue":"8","key":"7392_CR11","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1001\/jama.2020.12443","volume":"324","author":"NL Pereira","year":"2020","unstructured":"Pereira NL, Farkouh ME, So D, et al. Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: the TAILOR-PCI randomized clinical trial. JAMA. 2020;324(8):761\u201371.","journal-title":"JAMA"},{"key":"7392_CR12","doi-asserted-by":"crossref","unstructured":"Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med. 1999 [cited 2021 Feb 24];130:461\u201370. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/10075613\/","DOI":"10.7326\/0003-4819-130-6-199903160-00002"},{"key":"7392_CR13","doi-asserted-by":"crossref","unstructured":"Firth D. Bias reduction of maximum likelihood estimates. Biometrika. 1993 [cited 2021 Dec 1];80:27\u201338. Available from: https:\/\/academic.oup.com\/biomet\/article\/80\/1\/27\/228364","DOI":"10.1093\/biomet\/80.1.27"},{"key":"7392_CR14","doi-asserted-by":"crossref","unstructured":"Stanifer JW, Charytan DM, White J, et al. Benefit of ezetimibe added to simvastatin in reduced kidney function. J Am Soc Nephrol. 2017;28:3034\u201343. Available from: http:\/\/jasn.asnjournals.org\/content\/28\/10\/3034.abstract","DOI":"10.1681\/ASN.2016090957"},{"key":"7392_CR15","doi-asserted-by":"crossref","unstructured":"James S, Budaj A, Aylward P, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the platelet inhibition and patient outcomes (PLATO) trial. Circulation. 2010 [cited 2021 Feb 24];122:1056\u201367. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/20805430\/","DOI":"10.1161\/CIRCULATIONAHA.109.933796"},{"issue":"1","key":"7392_CR16","first-page":"121","volume":"176","author":"I Konstantinidis","year":"2016","unstructured":"Konstantinidis I, Nadkarni GN, Yacoub R, et al. Representation of patients with kidney disease in trials of cardiovascular interventions: an updated systematic review. JAMA Intern Med American Medical Association. 2016;176(1):121\u20134.","journal-title":"JAMA Intern Med American Medical Association"},{"key":"7392_CR17","doi-asserted-by":"crossref","unstructured":"Liang J, Wang Z, Shi D, et al. High clopidogrel dose in patients with chronic kidney disease having clopidogrel resistance after percutaneous coronary intervention. Angiology. 2015; 66:319\u201325. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/24913197\/","DOI":"10.1177\/0003319714538804"},{"key":"7392_CR18","doi-asserted-by":"crossref","unstructured":"Collet J-P, Cuisset T, Rang\u00e9 G, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med. 2012 [cited 2021 Jul 15];367:2100\u20139. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/23121439\/","DOI":"10.1056\/NEJMoa1209979"},{"key":"7392_CR19","doi-asserted-by":"crossref","unstructured":"Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA; 2011 [cited 2021 Jul 15];305:1097\u2013105. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/21406646\/","DOI":"10.1001\/jama.2011.290"},{"key":"7392_CR20","doi-asserted-by":"crossref","unstructured":"Sibbing D, Aradi D, Alexopoulos D, et al. Updated expert consensus statement on platelet function and genetic testing for guiding P2Y12 receptor inhibitor treatment in percutaneous coronary intervention. JACC Cardiovasc. Interv. 2019 [cited 2022 Sep 30]. p. 1521\u201337. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31202949\/","DOI":"10.1016\/j.jcin.2019.07.011"},{"key":"7392_CR21","doi-asserted-by":"crossref","unstructured":"Viviani Anselmi C, Briguori C, Roncarati R, et al. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease. JACC Cardiovasc Interv; 2013 [cited 2021 Feb 24];6:1166\u201375. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/24262617\/","DOI":"10.1016\/j.jcin.2013.06.010"},{"key":"7392_CR22","doi-asserted-by":"crossref","unstructured":"Wu Y, Zhou Y, Pan Y, et al. Impact of CYP2C19 polymorphism in prognosis of minor stroke or TIA patients with declined eGFR on dual antiplatelet therapy: CHANCE substudy. Pharmacogenomics J. 2018 [cited 2020 Aug 17];18:713\u201320. Available from: https:\/\/www.nature.com\/articles\/s41397-018-0018-4.","DOI":"10.1038\/s41397-018-0018-4"},{"key":"7392_CR23","doi-asserted-by":"crossref","unstructured":"Tabata N, Hokimoto S, Akasaka T, et al. Chronic kidney disease status modifies the association of CYP2C19 polymorphism in predicting clinical outcomes following coronary stent implantation. Thromb Res. 2014 [cited 2020 Nov 4];134:939\u201344. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/25201060\/","DOI":"10.1016\/j.thromres.2014.07.039"},{"key":"7392_CR24","doi-asserted-by":"crossref","unstructured":"Wang W, Shao C, Xu B, et al. CYP2C19 genotype has prognostic value in specific populations following coronary stenting. Ann Transl Med. 2021 [cited 2022 Feb 24];9:1066\u20131066. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/34422978\/","DOI":"10.21037\/atm-20-7724"},{"key":"7392_CR25","doi-asserted-by":"crossref","unstructured":"Wang H, Qi J, Li Y, et al. Pharmacodynamics and pharmacokinetics of ticagrelor vs . clopidogrel in patients with acute coronary syndromes and chronic kidney disease. Br J Clin Pharmacol. 2018 [cited 2020 Aug 17];84:88\u201396. Available from: http:\/\/doi.wiley.com\/","DOI":"10.1111\/bcp.13436"},{"key":"7392_CR26","doi-asserted-by":"crossref","unstructured":"Barbieri L, Pergolini P, Verdoia M, et al. Platelet reactivity in patients with impaired renal function receiving dual antiplatelet therapy with clopidogrel or ticagrelor. Vascul Pharmacol. 2016 [cited 2021 Feb 25];79:11\u20135. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26518440\/","DOI":"10.1016\/j.vph.2015.10.006"},{"key":"7392_CR27","doi-asserted-by":"crossref","unstructured":"Jeong KH, Cho JH, Woo JS, et al. Platelet reactivity after receiving clopidogrel compared with ticagrelor in patients with kidney failure treated with hemodialysis: a randomized crossover study. Am J Kidney Dis. 2015 [cited 2021 Feb 25];65:916\u201324. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/25622774\/","DOI":"10.1053\/j.ajkd.2014.11.023"},{"key":"7392_CR28","doi-asserted-by":"crossref","unstructured":"Alexopoulos D, Xanthopoulou I, Plakomyti TE, Goudas P, Koutroulia E, Goumenos D. Ticagrelor in clopidogrel-resistant patients undergoing maintenance hemodialysis. Am J Kidney Dis. 2012 [cited 2021 Feb 25]. p. 332\u20133. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/22658575\/","DOI":"10.1053\/j.ajkd.2012.05.001"},{"issue":"9","key":"7392_CR29","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.3390\/cells9092024","volume":"9","author":"JD Ravid","year":"2020","unstructured":"Ravid JD, Chitalia VC. Molecular mechanisms underlying the cardiovascular toxicity of specific uremic solutes. Cells. 2020;9(9):2024.","journal-title":"Cells"},{"key":"7392_CR30","doi-asserted-by":"crossref","unstructured":"Yang K, Du C, Wang X, et al. Indoxyl sulfate induces platelet hyperactivity and contributes to chronic kidney disease-associated thrombosis in mice. Blood. 2017;129:2667\u201379. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/28264799\/","DOI":"10.1182\/blood-2016-10-744060"},{"key":"7392_CR31","unstructured":"Yeh RW, Kereiakes DJ, Steg PG, et al. Benefits and risks of extended duration dual antiplatelet therapy after PCI in patients with and without acute myocardial infarction. J Am Coll Cardiol. 2015 [cited 2021 Mar 30];65:2211\u201321. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/25787199\/"},{"key":"7392_CR32","doi-asserted-by":"crossref","unstructured":"Galli M, Benenati S, Capodanno D, et al. Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Lancet. 2021 [cited 2022 Feb 21];397:1470\u201383. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33865495\/","DOI":"10.1016\/S0140-6736(21)00533-X"},{"key":"7392_CR33","doi-asserted-by":"crossref","unstructured":"Pereira NL, Rihal C, Lennon R, et al. Effect of CYP2C19 genotype on ischemic outcomes during oral P2Y12 inhibitor therapy: a meta-analysis. JACC Cardiovasc Interv. 2021 [cited 2022 Feb 21];14:739\u201350. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33744207\/","DOI":"10.1016\/j.jcin.2021.01.024"},{"issue":"23","key":"7392_CR34","doi-asserted-by":"publisher","first-page":"5506","DOI":"10.3390\/jcm10235506","volume":"10","author":"F Condello","year":"2021","unstructured":"Condello F, Sturla M, Terzi R, Polimeni A, Stefanini GG. Walking the line with ticagrelor: meta-analysis comparing the safety and efficacy of ticagrelor monotherapy after a short course of ticagrelor-based dual antiplatelet therapy versus standard therapy in complex percutaneous coronary intervention. J Clin Med. 2021;10(23):5506.","journal-title":"J Clin Med"},{"key":"7392_CR35","doi-asserted-by":"crossref","unstructured":"Stefanini GG, Briguori C, Cao D, et al. Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD. Eur Heart J. 2021 [cited 2022 Sep 30];42:4683\u201393. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/34423374\/","DOI":"10.1093\/eurheartj\/ehab533"},{"key":"7392_CR36","doi-asserted-by":"crossref","unstructured":"Limdi NA, Cavallari LH, Lee CR, et al. Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data. Pharmacogenomics J. 2020 [cited 2022 Sep 30];20:724\u201335. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32042096\/","DOI":"10.1038\/s41397-020-0162-5"},{"issue":"8","key":"7392_CR37","doi-asserted-by":"publisher","first-page":"e011990","DOI":"10.1161\/CIRCINTERVENTIONS.122.011990","volume":"15","author":"T Kuno","year":"2022","unstructured":"Kuno T, Fujisaki T, Shoji S, et al. Comparison of unguided de-escalation versus guided selection of dual antiplatelet therapy after acute coronary syndrome: a systematic review and network meta-analysis. Circ Cardiovasc Interv. 2022;15(8):e011990.","journal-title":"Circ Cardiovasc Interv"},{"key":"7392_CR38","doi-asserted-by":"crossref","unstructured":"Condello F. Uncertainties about platelet function and genetic testing for guiding dual antiplatelet therapy in percutaneous coronary intervention J Thromb Thrombolysis. 2022 Feb; 53(2): 514\u20136.","DOI":"10.1007\/s11239-021-02543-y"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-022-07392-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-022-07392-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-022-07392-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T06:22:50Z","timestamp":1715926970000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-022-07392-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,29]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["7392"],"URL":"https:\/\/doi.org\/10.1007\/s10557-022-07392-2","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"type":"print","value":"0920-3206"},{"type":"electronic","value":"1573-7241"}],"subject":[],"published":{"date-parts":[[2022,11,29]]},"assertion":[{"value":"11 October 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committees\/Institutional Review Boards of all participating sites.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Roy O. Mathew, MD: No relevant disclosures.Mandeep S. Sidhu, MD, MBA: Astra Zeneca 2019 SAB, Sanofi-Regeneron 2019 SAB.Michael E. Farkouh, MD: research support from Amen, Novartis and Novo Nordisk.Charanjit S. Rihal, MD: No disclosures.Ryan Lennon, MS: No disclosures.Mohammad El-Hajjar, MD: No disclosures.Neil Yager, DO: No disclosures.Radmila Lyubarova, MD: No disclosures.Yves Rosenberg, MD: No disclosures.Khaled Abdul-Nour, MD: No disclosures.Steven Weitz, MD: No disclosures.D. Fearghas O\u2019Cochlain, MD: No disclosures.Vishu Murthy, MD: No disclosures.Justin Levisay, MD: Previous proctoring relationship with Boston Scientific which has ceased with the Lotus valve being pulled from the Market.Kevin Marzo, MD: No disclosures.John J. Graham, MD: Honoraria: Astra Zeneca, Teleflex Medical, Boston Scientific.Vladim\u00edr D\u017eav\u00edk, MD: No relevant disclosures.Derek So, MD: He has received unrestricted grant support (physician-initiated grant) from Eli Lilly Canada; is a member of the advisory board and has received honoraria from AstraZeneca Canada; is a member of the advisory board for Bayer Canada; has received unrestricted grant support (physician-initiated grant) from Spartan Biosciences; has received unrestricted grant support (physician-initiated grant) from Aggredyne; and has received unrestricted grant support (physician-initiated grant) from Diapharma\/Roche Diagnostics.Shaun Goodman, MD: Shaun G. Goodman reports research grant support (e.g., steering committee or data and safety monitoring committee) and\/or speaker\/consulting honoraria (e.g., advisory boards) from: Amgen, Anthos Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CSL Behring, Daiichi-Sankyo\/American Regent, Eli Lilly, Esperion, Ferring Pharmaceuticals, HLS Therapeutics, JAMP Pharma, Merck, Novartis, Novo Nordisk A\/C, Pendopharm\/Pharmascience, Pfizer, Regeneron, Sanofi, Servier, Valeo Pharma; and salary support\/honoraria from the Heart and Stroke Foundation of Ontario\/University of Toronto (Polo) Chair, Canadian Heart Research Centre and MD Primer, Canadian VIGOUR Centre, Cleveland Clinic Coordinating Centre for Clinical Research, Duke Clinical Research Institute, New York University Clinical Coordinating Centre, PERFUSE Research Institute, TIMI Study Group (Brigham Health).Naveen Pereira, MD: Funding for this research was provided by the NIH (grants U01HL128606 and U01HL128626).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"Its contents are solely the responsibility of the authors and do not necessarily represent official views of the Department of Veterans Affairs, National Heart, Lung, and Blood Institute, the National Institutes of Health, or the Department of Health and Human Services. Parts of this manuscript were presented as a recorded abstract for the American College of Cardiology Scientific Session 2021.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}